Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-155 · 1 trial · 1 indication
The Maximum Tolerated Dose (MTD) and/or the Recommended Phase Two Dose (RPTD) of ABBV-155 will be determined during the dose escalation phase (Part 1).
ORR is defined as the percentage of participants with documented best response partial response (PR) or better according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
| Arm | Type | Description |
|---|---|---|
| Escalation 1a: ABBV-155 | EXPERIMENTAL | Participants will be administered ABBV-155 (various doses). |
| Escalation 1b: ABBV-155 + paclitaxel or docetaxel | EXPERIMENTAL | Participants will be administered ABBV-155 (various doses) in combination with paclitaxel or docetaxel . |
| Expansion 2a: ABBV-155 in SCLC | EXPERIMENTAL | Description: Participants with small cell lung cancer (SCLC) will administer ABBV-155 (at the recommended Phase 2 dose). |
| Expansion 2b: ABBV-155 + paclitaxel in Breast Cancer | EXPERIMENTAL | Participants with breast cancer will be administered ABBV-155 (at the recommended Phase 2 dose identified for combination with paclitaxel in part 1b) in combination with paclitaxel. |
| Expansion 2b: ABBV-155 + docetaxel in NSCLC | EXPERIMENTAL | Participants with non-small cell lung cancer (NSCLC) will be administered ABBV-155 (at or near the recommended Phase 2 dose identified for combination with paclitaxel in part 1b) in combination with docetaxel. |
| Name | Type | Description |
|---|---|---|
| ABBV-155 | DRUG | Intravenous (IV) Infusion |
| Paclitaxel | DRUG | Intravenous (IV) Infusion |
| Docetaxel | DRUG | Intravenous (IV) Infusion |
Inclusion Criteria: * Has a histologic or cytologic diagnosis of a malignant solid tumor. * Participants enrolled in Part 2a (monotherapy, dose expansion) must have small cell lung cancer (SCLC) diagnosis; participants enrolled to Part 2b (combination therapy, dose expansion) must have either NSCLC...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ABBV-155 is an investigational small molecule being studied for the treatment of advanced solid tumors. It is being developed by AbbVie Inc. and has completed a Phase 1 clinical trial in adults with relapsed and/or refractory solid tumors.
The molecular target of ABBV-155 has not been disclosed. It is a small molecule being evaluated in oncology for advanced solid tumors, but its specific mechanism of action has not been publicly detailed.
ABBV-155 is being developed by AbbVie Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker ABBV. The company has conducted a Phase 1 clinical trial of this investigational drug in advanced solid tumors.
ABBV-155 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study of ABBV-155, alone and in combination with taxane therapy, has been completed.
ABBV-155 has been studied in one clinical trial, NCT03595059, titled 'A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors.' This Phase 1 study enrolled 168 participants and has been completed.
No alternative names for ABBV-155 have been disclosed. It is identified solely by its development code ABBV-155 in clinical trial records and by its developer, AbbVie Inc.